Daito Pharmaceutical Co.,Ltd., June-August (1Q) Ordinary Profit Decreases by 10%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Oct 11, 2024 3:00 pm JST Earnings

4577 Daito Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

Daito Pharmaceutical Co.,Ltd. <4577> [TSE-P] announced its financial results after the market closed on October 11th (15:00). The consolidated ordinary profit for the first quarter of the fiscal year ending May 2025 (June to August) decreased by 10.0% from the same period last year to 983 million yen. However, The progress rate against the 3.5 billion yen full-year plan was 28.1%, almost the same as the five-year average of 30.0%.

In the most recent three-month period, from June to August (1Q), the operating profit margin worsened from 8.9% in the same period last year to 6.7%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jun - Aug, 2022	12,041	1,501	1,475	946	59.7	53.6	Oct 13, 2022	J-GAAP
Jun - Aug, 2023	12,178	1,080	1,092	683	43.3	47.2	Oct 12, 2023	J-GAAP
Jun - Aug, 2024	12,678	849	983	618	40.4	ー	Oct 11, 2024	J-GAAP
YoY	+4.1%	-21.4%	-10.0%	-9.5%	-6.6%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jun - Nov, 2023	24,110	2,289	2,314	1,552	98.2	30	Jan 12, 2024	J-GAAP
Jun - Nov, 2024 Guidance	ー	ー	ー	ー	－	35	Jul 12, 2024	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
May, 2023	45,101	5,207	5,169	3,600	227.6	54.55	Jul 14, 2023	J-GAAP
May, 2024	46,895	3,894	3,923	3,295	210.0	60	Jul 12, 2024	J-GAAP
May, 2025 Guidance	49,000	3,500	3,500	2,300	150.4	70	Jul 12, 2024	J-GAAP
YoY	+4.5%	-10.1%	-10.8%	-30.2%	-28.4%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jun - Aug, 2023	12,178	1,080	1,092	683	43.3	8.9	Oct 12, 2023	J-GAAP
Sep - Nov, 2023	11,932	1,209	1,222	869	55.0	10.1	Jan 12, 2024	J-GAAP
Dec - Feb, 2023	10,552	816	808	787	49.9	7.7	Apr 12, 2024	J-GAAP
Mar - May, 2024	12,233	789	801	956	60.9	6.4	Jul 12, 2024	J-GAAP
Jun - Aug, 2024	12,678	849	983	618	40.4	6.7	Oct 11, 2024	J-GAAP
YoY	+4.1%	-21.4%	-10.0%	-9.5%	-6.6%